DEVELOPING THE 'ON' SWITCH FOR IMMUNO-ONCOLOGY

Serial Number 98935691
688

Registration Progress

Application Filed
Jan 3, 2025
Under Examination
Sep 30, 2025
Approved for Publication
Aug 5, 2025
Published for Opposition
Aug 5, 2025
Registered

Trademark Image

DEVELOPING THE 'ON' SWITCH FOR IMMUNO-ONCOLOGY

Basic Information

Serial Number
98935691
Filing Date
January 3, 2025
Published for Opposition
August 5, 2025
Drawing Code
4

Status Summary

Current Status
Active
Status Code
688
Status Date
Sep 30, 2025
Application
Pending
Classes
005 042

Rights Holder

Replimune Limited

78
Address
69 Innovation Dr., Milton Park, Abingdon
Oxfordshire OX144RQ
GB

Ownership History

Replimune Limited

Original Applicant
78
Oxfordshire GB

Replimune Limited

Owner at Publication
78
Oxfordshire GB

Legal Representation

Attorney
Melanie Howard

USPTO Deadlines

No Upcoming Deadlines

No upcoming deadlines found for this trademark.

Application History

8 events
Date Code Type Description Documents
Sep 30, 2025 NOAM E NOA E-MAILED - SOU REQUIRED FROM APPLICANT Loading...
Aug 5, 2025 NPUB E OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED Loading...
Aug 5, 2025 PUBO A PUBLISHED FOR OPPOSITION Loading...
Jul 30, 2025 NONP E NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED Loading...
Jun 27, 2025 CNSA P APPROVED FOR PUB - PRINCIPAL REGISTER Loading...
Jun 14, 2025 DOCK D ASSIGNED TO EXAMINER Loading...
Jun 3, 2025 NWOS I NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Loading...
Jan 3, 2025 NWAP I NEW APPLICATION ENTERED Loading...

Detailed Classifications

Class 005
Biological preparations in the nature of viruses for the treatment of cancer, tumors, infectious, oncological, autoimmune, and immune system diseases and disorders; biological preparations in the nature of viruses for the treatment of cancer; biological preparations in the nature of viruses for inducing immune response; pharmaceuticals, namely, pharmaceutical preparations and pharmaceutical substances for the treatment of cancer, tumors, infectious, oncological, autoimmune, and immune system diseases and disorders; pharmaceuticals, namely, anti-infectives for the treatment of cancer, tumors, infectious, oncological, autoimmune, and immune system diseases and disorders; pharmaceuticals for the treatment of cancer; pharmaceutical preparations for inducing immune response; vaccines; immunotherapy products, namely, pharmaceutical products for the prevention and treatment of cancer, tumors, infectious, oncological, autoimmune, and immune system diseases and disorders; gene therapy products, namely, therapeutics for the treatment of cancer, tumors, infectious, oncological, autoimmune, and immune system diseases and disorders
Class 042
Pharmaceutical drug research and development services; research and development of vaccines and medicines; information, advisory and consultancy services relating to the aforesaid

Additional Information

Pseudo Mark
DEVELOPING THE ON SWITCH FOR IMMUNOONCOLOGY

Classification

International Classes
005 042